Evidence map›Paper›PMID 39535522›Full record

ArticleCurrent protocols2024

Efficient CRISPR/Cas9 Knock-in Approaches for Manipulation of Endogenous Genes in Human B Lymphoma Cells.

Laura A Murray-Nerger, Benjamin E Gewurz

Abstract read
In one paragraph

Article in Current protocols, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Laura A Murray-NergerDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Benjamin E GewurzDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID https://orcid.org/0000-0002-3965-3418

Funding

Targeting the Epigenetic and Metabolic Control of EBV-Epithelial CancersP01CA269043 · NCI · WISTAR INSTITUTE · PI Samantha Standish Soldan · 2023 to 2026
$12.0M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
B cell determinants of EBV latency (supplement)U01CA275301 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Ethel Cesarman, Benjamin Elison Gewurz · 2022 to 2026
$4.0M
Epstein-Barr virus LMP1 mediated oncogenicityR01CA228700 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Benjamin Elison Gewurz · 2019 to 2026
$3.3M
Regulation of the Epstein-Barr Virus Lytic SwitchR01AI164709 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Benjamin Elison Gewurz · 2021 to 2026
$3.1M
Metabolic Network Remodeling in Epstein-Barr Virus LymphomagenesisR01AI137337 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI GEWURZ, BENJAMIN ELISON · 2018 to 2022
$2.2M
Epstein-Barr Virus Driven Tonsillar Versus Peripheral B-cell One-Carbon Metabolic Network RemodelingR01DE033907 · NIDCR · BRIGHAM AND WOMEN'S HOSPITAL · PI Benjamin Elison Gewurz · 2024 to 2026
$1.5M
Systematic CRISPR Analysis of EBV Lymphoma Resistance Pathways to Natural Killer Cell LysisR21AI181873 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI GEWURZ, BENJAMIN ELISON · 2024 to 2025
$492k
Characterization of Epstein-Barr Virus Subversion of the Host SMC5/6 Restriction PathwayR21AI170751 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI GEWURZ, BENJAMIN ELISON · 2023 to 2024
$492k
Defining how the DNA- and RNA-binding protein SFPQ represses Epstein-Barr Virus lytic reactivationF32AI172329 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI MURRAY-NERGER, LAURA · 2022 to 2024
$147k
NCI NIH HHS P01 CA269043NCI NIH HHS R01 CA228700NCI NIH HHS U01 CA275301NIAID NIH HHS F32 AI172329NIAID NIH HHS R01 AI137337NIAID NIH HHS R01 AI164709NIAID NIH HHS R21 AI170751NIAID NIH HHS R21 AI181873NIAID NIH HHS T32 AI007245NIDCR NIH HHS R01 DE033907
6 · The paper itself

Abstract

Precise understanding of temporally controlled protein-protein interactions, localization, and expression is often difficult to achieve using traditional overexpression techniques. Recent advances have made CRISPR-based knock-in approaches efficient, which enables rapid derivation of cells with tagged endogenous proteins. However, the high degree of variability in knock-in efficiency across cell types and gene loci poses challenges, in particular with B lymphocytes, which are refractory to lipid transfection. Here, we present detailed protocols for efficient B lymphoma cell CRISPR/Cas9-mediated knock-in. We address knock-in efficiency in two ways. First, we provide a detailed approach for assessing cutting efficiency to select the most efficient single guide RNA for the gene region of interest. Second, we provide detailed approaches for tagging endogenous proteins with a fluorescent marker or instead for co-expressing them with an unlinked fluorescent marker. Either approach facilitates downstream selection of single-cell or bulk populations with the desired knock-in, particularly when knock-in efficiency is low. The utility of this approach is demonstrated via examples of engineering tags onto endogenous protein N- or C-termini, together with downstream analyses. We anticipate that this workflow can be applied more broadly to other cell types for efficient knock-in into endogenous loci. © 2024 Wiley Periodicals LLC. Basic Protocol 1: Choosing an optimal knock-in target site and single guide RNA (sgRNA) design Basic Protocol 2: Assessment of Cas9 editing efficiency at the desired B cell genomic knock-in site Basic Protocol 3: Cloning the sgRNA dual guide construct Basic Protocol 4: Repair template design and cloning Basic Protocol 5: Electroporation and selection of engineered B cells Basic Protocol 6: Single-cell cloning of engineered B cells.

Indexed as

CRISPR-Cas SystemsGene Knock-In TechniquesLymphoma, B-CellB-LymphocytesCell Line, TumorHumansRNA, Guide, CRISPR-Cas SystemsRNA, Guide, CRISPR-Cas SystemsB cellCRISPR engineeringCRISPR‐mediated knock‐indegron tagendogenous locusfluorescent protein tag

Identifiers

PMID39535522
PMCPMC11567056

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.